IONIS PHARMACEUTICALS INC (IONS) Stock Price, Quote, News and Overview
NASDAQ:IONS - Nasdaq - US4622221004 - Common Stock - Currency: USD
IONS Quote, Performance and Key Statistics
IONIS PHARMACEUTICALS INC
NASDAQ:IONS (2/4/2025, 8:00:02 PM)
After market: 31.64 0 (0%)31.64
-0.49 (-1.53%)
The current stock price of IONS is 31.64 USD. In the past month the price decreased by -9.11%. In the past year, price decreased by -38.44%.
IONS Latest News, Press Releases and Analysis
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2024 achievements and previewed important milestones...
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview...
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
One analyst says the six-month study was too short and the benefits could appear over time.
IONS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About IONS
Company Profile
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 927 full-time employees. The firm has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. The company has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Company Info
IONIS PHARMACEUTICALS INC
2855 Gazelle Court
Carlsbad CALIFORNIA 92010 US
CEO: Brett P. MONIA
Employees: 927
Company Website: https://www.ionis.com/
Investor Relations: https://ir.ionispharma.com
Phone: 17609319200
IONS FAQ
What is the stock price of IONS?
The current stock price of IONS is 31.64 USD.
What is the symbol for IONIS PHARMACEUTICALS INC stock?
The exchange symbol of IONIS PHARMACEUTICALS INC is IONS and it is listed on the Nasdaq exchange.
On which exchange is IONS stock listed?
IONS stock is listed on the Nasdaq exchange.
Is IONS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IONS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IONS.
Does IONS stock pay dividends?
IONS does not pay a dividend.
When does IONS stock report earnings?
IONS will report earnings on 2025-02-19, after the market close.
What is the Price/Earnings (PE) ratio of IONS?
IONS does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.44).
What is the Short Interest ratio of IONS stock?
The outstanding short interest for IONS is 6.63% of its float.
IONS Technical Analysis
IONS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IONS. While IONS seems to be doing ok healthwise, there are quite some concerns on its profitability.
IONS Financial Highlights
Over the last trailing twelve months IONS reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS decreased by 36.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.65% | ||
| ROE | -54.16% | ||
| Debt/Equity | 1.86 |
IONS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to IONS. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of -38.64% and a revenue growth -2.73% for IONS